AgomAb Therapeutics NV (AGMB) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$12.26

From 52W high−31.71%

Volume250623.00

Market cap$599.35M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$12.26

From 52W high

−31.71%

Volume

250623.00

Market cap

$599.35M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.5x

P/E (TTM)

—

RSI (14)

39.2

MomentumView details →

1D Return

+0.75%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−6.5x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

4.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−47.78%

ROA (TTM)

−40.69%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−1.59%

EBITDA YoY

—

MomentumView details →

1D Return

+0.75%

YTD Return

—

1Y Return

—

RSI (14)

39.2

vs 50D SMA

−12.11%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

6.52x

Quick Ratio

6.52x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.91

EPS Surprise

−137.55%

Beats (12Q)

0/12

Next Q EPS Est

−$1.28

Avg Surprise (4Q)

−72.16%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsMar 3, 2027 →

Latest newsMore news →

Agomab Therapeutics announced positive Phase 1 results for AGMB-447 in idiopathic pulmonary fibrosis patients and submitted a CTA for the Phase 2 INSPIRIA study, which it intends to initiate before year-end.6d ago

Similar companies

Bright Minds Biosciences Inc.DRUG CytomX Therapeutics, Inc.CTMX CorMedix Inc.CRMD Shattuck Labs, Inc.STTK Phathom Pharmaceuticals, Inc.PHAT 3D Medicines Inc.01244.HK Find similar companies →

Latest newsMore news →

Agomab Therapeutics announced positive Phase 1 results for AGMB-447 in idiopathic pulmonary fibrosis patients and submitted a CTA for the Phase 2 INSPIRIA study, which it intends to initiate before year-end.6d ago